Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 30, 2021 at 09:06 am EDT
Share
Realcan Pharmaceutical Group Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 12,710.952 million compared to CNY 12,700.824 million a year ago. Operating income was CNY 400.642 million compared to CNY 479.154 million a year ago. Net income was CNY 115.556 million compared to CNY 153.492 million a year ago. Basic earnings per share from continuing operations was CNY 0.077 compared to CNY 0.102 a year ago.
Realcan Pharmaceutical Group Co., Ltd., formerly REALCAN PHARMACEUTICAL CO., LTD., is a China-based medical service provider. The Company operates its businesses through three segments. The Medical segment is engaged in the provision of Chinese medicine materials, Chinese medicine tablets, Chinese patent medicines, chemical drug materials, chemical preparations, antibiotics, biochemical pharmaceuticals, biological products, psychotropic substances, anesthetic medicines and peptide hormones. The Equipment is engaged in the provision of medical equipment. The Mobile Medical segment is engaged in the provision of medical and logistics services and mobile medical information services. The Company conducts its businesses mainly within domestic markets, with Shandong as its main market.
REALCAN PHARMACEUTICAL GROUP CO., LTD. 
